Abstract: A vaccine for activating CD8 T cells including Bacillus Calmette-Guérin (BCG bacteria) which express a protein derived from a pathogenic microorganism as an active ingredient is beneficial because it can activate pathogenic microorganism-derived-antigen-specific CD8 T cells

Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.

Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.

Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.

Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which a third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.

Abstract: This invention provides a recombinant BCG vaccine transformed by an expression vector having polynucleotide coding for exogenous antigenic protein, characterized in that, the BCG vaccine is used for initial antigen stimulus in immune induction by plural antigen stimulations and also provides a method for the immune induction where the initial antigen stimulus is carried out by the said BCG vaccine and one or more additional antigenic stimulation(s) is/are carried out by non-BCG vaccine expressing the same antigenic protein.

Abstract: The invention provides a recombinant vaccinia virus strain DIs that possesses a polynucleotide encoding a foreign antigenic protein in the non-essential gene region of the chromosome DNA and expresses the antigenic protein; and provides a highly-safe, vaccinia virus vaccine containing the recombinant virus strain DIs as the active ingredient. The invention also provides a method of using the vaccinia virus strain DIs as a vector for protein expression.

Abstract: The present invention provides a preventive and therapeutic antiviral drug for AIDS, hepatitis B, hepatitis c and influenza containing MEP-F (metalloendopeptidase-F) and proteases (protein decomposition enzymes) as effective ingredients.

Abstract: A vaccine containing Mycobacterium bovis BCG which secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of a secretory protein, a carrier, having a signal peptide. BCG constituting the present invention secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of an .alpha.-antigen derived from mycobacteria. Said fusion protein has significantly increased antigenicity and immunogenicity. Therefore, when it is inoculated into animals, it is efficiently recognized by B cells which recognize said antigen, thereby effectively inducing the production of an antibody to said antigen. When said BCG itself is inoculated into animals, it continuously secretes said fusion protein in the bodies of the animals while continuously propagating therein. Therefore, said BCG is an extremely useful vaccine.

Abstract: A vaccine containing Mycobacterium bovis BCG which secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of a secretory protein, a carrier, having a signal peptide. BCG constituting the present invention secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of an .alpha.-antigen derived from mycobacteria. Said fusion protein has significantly increased antigenicity and immunogenicity. Therefore, when it is inoculated into animals, it is efficiently recognized by B cells which recognize said antigen, thereby effectively inducing the production of an antibody to said antigen. When said BCG itself is inoculated into animals, it continuously secretes said fusion protein in the bodies of the animals while continuously propagating therein. Therefore, said BCG is an extremely useful vaccine.

Abstract: A pharmaceutical composition against AIDS, which contains, as an active ingredient, an antibody capable of recognizing glycolipid derived from Echinoidea.

Abstract: A high-tension high-toughness steel excellent in resistance to delayed fracture which consists essentially of 0.15 to 0.50% of C, up to 1.50% of Si, 0.20 to 1.50% of Mn, up to 2.00% of Cr, 0.0005 to 0.0030% of B, 0.005 to 0.10% of acid-soluble Al, up to 0.010% of P, up to 0.0020% of N, 0.010 to 0.050% of Ti and the balance iron and inevitable impurities, and has a tempered martensitic structure obtained by quenching and tempering.

Abstract: The present invention relates to an improvement in the lapping method of wafer-like work pieces in a lapping machine to lap the work pieces by sandwiching them between relatively rotatable upper and lower surface plates, in which the thickness of the work pieces under lapping is determined by an in-machine manner with a sensor mounted on the upper surface plate. Different from conventional lapping methods with an in-machine measurement of the thickness, the thickness of the work pieces is computed only once at regular intervals corresponding to one relative revolution of the surface plates so that the errors due to the operation per se of the lapping machine such as the undulated revolution of the surface plates, vibration of the machine and the like can be eliminated and very much improved control means for the thickness of the work pieces under lapping can be obtained.